Immuno-oncology

#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

Summit: What advances are driving immuno-oncology drug discovery?

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More

#News

Immunotherapy
#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

Register now for immuno-oncology summit

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More

#News

#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

Summit explores advances driving immuno-oncology drug discovery

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More

#News

Immunity
#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

Register now: Advances driving immuno-oncology drug discovery

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More

#News

#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

Summit: Advances driving immuno-oncology drug discovery

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More

#News

#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

The advances driving immuno-oncology drug discovery

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More

Webinar date:
Sponsored by Sino Biological
#Webinars

#Cancer research #Gut microbiome #Immuno-oncology #Melanoma #Non-small cell lung cancer (NSCLC)

Improving response: Microbiome-based approaches to checkpoint inhibitor resistance

Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer.   Harnessing the microbiome is emerging as a promising strategy to enhance the body’s response to certain anti-cancer therapies and to mitigate treatment-related toxicities (1). Clinical evidence indicates that gut microbiome composition contributes to patient… Read More

#Cancer Research #Exclusive Content

T cells attack a cancer cell
#Anti-inflammatory #Canada #GPCRs #Immuno-oncology

Kainova secures funding to develop GPCR-targeting therapies 

Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies.  This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies.  The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is currently progressing in an ongoing Phase I/II DOMISOL trial for… Read More

#Business & Investment #News

Cancer cells
#Cancer research #GSK #Immuno-oncology

GSK partners with LTZ to develop myeloid cell engagers 

GSK has announced a strategic collaboration with biotechnology company LTZ to advance novel myeloid cell engagers (MCEs) in oncology.   The research collaboration aims to develop up to four potential first-in-class MCE therapies targeting haematologic cancers and solid tumours. The agreement grants GSK an exclusive option to license worldwide development and commercial rights… Read More

#Business & Investment #News

Cancer cells
#AI #Cancer #Drug discovery #Immuno-oncology

One to watch: How Aulos is advancing immunotherapy cancer treatments  

DDW Editor Reece Armstrong speaks to Aron Knickerbocker, CEO of Aulos Bioscience, about the company’s efforts in the immuno-oncology field and how it is hoping to revitalise a therapeutic area that initially held promise many years ago.  The number of available treatment options for cancer patients has risen drastically since… Read More

#Exclusive Content

#Immuno-oncology #Immunotherapy #Oncology #Personalised medicine

Navigating the landscape of immunotherapy

Giusy Di Conza, Head of Research at iOnctura, explores the challenges of current immunotherapy approaches for cancer and where opportunity lies. Immunotherapy has transformed modern oncology. Immune checkpoint inhibitors like pembrolizumab and nivolumab revolutionised melanoma treatment by enhancing immune responses; ensuring it could become a manageable disease - with improved… Read More

#Cancer Research #Exclusive Content

Vaccine vial and syringe
#Cancer vaccine #GSK #Immuno-oncology #Oncology #University of Oxford

Oxford and GSK launch £50m cancer vaccines programme

GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines.  The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and builds on Oxford’s… Read More

#Business & Investment #Cancer Research #News

Cancer cells
#AstraZeneca #Cancer research #Guide #Immune response #Immuno-oncology #Immunotherapy #Immutep #Interview #Oncology #OncologyCancer research

Podcast: Breakthroughs and opportunities in cancer research

This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More

#News

#Career #Immuno-oncology #Oncology #Recruitment

Building an immuno-oncology talent pipeline

Jamie Gould, Consultant at The RSA Group, explores the talent landscape of the immuno-oncology sector. Immuno-oncology harnesses the power of the body’s immune system to fight cancer. This exciting field is rapidly evolving and already delivering a revolution in cancer therapeutics with a steady stream of recent approvals. In June… Read More

#Business & Investment #Exclusive Content

#Autoimmune disease #Cell therapy #Immuno-oncology #Kiji Therapeutics #Mergers and acquisitions #Monoclonal antibodies #REGiMMUNE #Stem cells

REGiMMUNE and Kiji Therapeutics announce intention to merge

Biopharmaceutical company REGiMMUNE and biotech Kiji Therapeutics have announced an intention to merge, creating a global Treg specialist that will target multiple indications. The new company, called REGiMMUNE/Kiji TX will combine the complimentary portfolio of platforms and therapies to create an international Treg biotech. Both companies have been focused on… Read More

#Business & Investment #News

FDA
#Astellas Pharma #Biomarkers #FDA #Immuno-oncology #Oncology

FDA approves CLDN18.2-targeted treatment for gastric cancer

The US Food and Drug Administration (FDA) has approved Vyloy (zolbetuximab-clzb) for locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults whose tumours are claudin… Read More

#News #Regulatory